Geron Co. (NASDAQ:GERN - Get Free Report) has received a consensus recommendation of "Buy" from the eleven brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $7.25.
GERN has been the subject of a number of recent analyst reports. Needham & Company LLC lifted their price objective on shares of Geron from $6.00 to $7.00 and gave the company a "buy" rating in a report on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Geron in a research note on Tuesday, December 10th. Finally, Barclays upgraded Geron to a "strong-buy" rating in a research report on Friday, November 29th.
Check Out Our Latest Stock Analysis on GERN
Geron Stock Performance
Shares of NASDAQ GERN traded up $0.04 during midday trading on Friday, reaching $2.60. 4,166,860 shares of the stock were exchanged, compared to its average volume of 11,423,688. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -8.11 and a beta of 0.53. The firm has a 50-day simple moving average of $3.21 and a two-hundred day simple moving average of $3.91. Geron has a twelve month low of $1.64 and a twelve month high of $5.34.
Institutional Trading of Geron
A number of institutional investors have recently made changes to their positions in GERN. SBI Securities Co. Ltd. purchased a new position in Geron in the 4th quarter valued at $28,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Geron in the fourth quarter valued at about $36,000. Fifth Lane Capital LP purchased a new position in shares of Geron in the fourth quarter worth about $53,000. Readystate Asset Management LP acquired a new position in Geron during the third quarter worth about $58,000. Finally, Rovin Capital UT ADV grew its stake in Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 3,660 shares in the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.
About Geron
(
Get Free ReportGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Articles
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
